Richard Svensson
Projektledare vid Institutionen för farmaci; Läkemedelsformulering
- Telefon:
- 018-471 47 44
- E-post:
- richard.svensson@farmaci.uu.se
- Besöksadress:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postadress:
- Box 580
751 23 UPPSALA
Ladda ned kontaktuppgifter för Richard Svensson vid Institutionen för farmaci; Läkemedelsformulering
Mer information visas för dig som medarbetare om du loggar in.
Publikationer
Senaste publikationer
- Discovery and Hit-to-Lead Optimization of Benzothiazole Scaffold- Based DNA Gyrase Inhibitors with Potent Activity against Acinetobacter baumannii and Pseudomonas aeruginosa (2023)
- Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy (2023)
- New Dual Inhibitors of Bacterial Topoisomerases with Broad-Spectrum Antibacterial Activity and In Vivo Efficacy against Vancomycin-Intermediate Staphylococcus aureus (2023)
- Monitoring drug–target interactions through target engagement-mediated amplification on arrays and in situ (2022)
- Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress (2022)
Alla publikationer
Artiklar
- Discovery and Hit-to-Lead Optimization of Benzothiazole Scaffold- Based DNA Gyrase Inhibitors with Potent Activity against Acinetobacter baumannii and Pseudomonas aeruginosa (2023)
- Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy (2023)
- New Dual Inhibitors of Bacterial Topoisomerases with Broad-Spectrum Antibacterial Activity and In Vivo Efficacy against Vancomycin-Intermediate Staphylococcus aureus (2023)
- Monitoring drug–target interactions through target engagement-mediated amplification on arrays and in situ (2022)
- Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress (2022)
- Inhibition of prolyl oligopeptidase (2022)
- Broad-Spectrum Antidote Discovery by Untangling the Reactivation Mechanism of Nerve-Agent-Inhibited Acetylcholinesterase (2022)
- Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer (2020)
- Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy (2020)
- Methyl sulfonamide substituents improve the pharmacokinetic properties of bicyclic 2-pyridone based Chlamydia trachomatis inhibitors (2019)
- Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound (2018)
- Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib (2018)
- A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (2018)
- An imidazole based H-Phe-Phe-NH2 peptidomimetic with anti-allodynic effect in spared nerve injury mice (2018)
- Impact of N-methylation of the substance P 1-7 amide on anti-allodynic effect in mice after peripheral administration (2017)
- Importance of N-and C-terminal residues of substance P 1-7 for alleviating allodynia in mice after peripheral administration (2017)
- Global Kinetic Mechanism of Microsomal Glutathione Transferase 1 and Insights into Dynamic Enzyme Activation (2017)
- N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors. (2017)
- Aryl Sulfonamide Inhibitors of Insulin-Regulated Aminopeptidase Enhance Spine Density in Primary Hippocampal Neuron Cultures (2016)
- Thiazolino 2-Pyridone Amide Inhibitors of Chlamydia trachomatis Infectivity (2016)
- Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1 (2016)
- Preclinical Characterization of Acyl Sulfonimidamides (2015)
- Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo (2015)
- Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues (2014)
- MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool (2014)
- Achiral Pyrazinone-Based Inhibitors of the Hepatitis C Virus NS3 Protease and Drug-Resistant Variants with Elongated Substituents Directed Toward the S2 Pocket (2014)
- Vulnerability of Glioblastoma Cells to Catastrophic Vacuolization and Death Induced by a Small Molecule (2014)
- Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles (2014)
- Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2–P1′ Region (2014)
- Impact of Stereospecific Intramolecular Hydrogen Bonding on Cell Permeability and Physicochemical Properties (2014)
- Constrained H-Phe-Phe-NH2 Analogues With High Affinity to the Substance P 1-7 Binding Site and With Improved Metabolic Stability and Cell Permeability (2013)
- The value of selected in vitro and in silico methods to predict acute oral toxicity in a regulatory context (2013)
- Optimizing Solubility and Permeability of a Biopharmaceutics Classification System (BCS) Class 4 Antibiotic Drug Using Lipophilic Fragments Disturbing the Crystal Lattice (2013)
- In Vitro and In Vivo Activities of 2-Aminopyrazines and 2-Aminopyridines in Experimental Models of Human African Trypanosomiasis (2013)
- Structure-Activity Relationships of Synthetic Cordycepin Analogues as Experimental Therapeutics for African Trypanosomiasis (2013)
- In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug-Drug Interactions (2012)
- Integrated cell models for prediction of drug transport and drug metabolism in the human hepatocyte (2010)
- Target Engagement-Mediated Amplification for Monitoring Drug-Target Interactions in Situ
